MannKind - MNKD Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings or view top-rated stocks.

1 analysts have issued 1 year price objectives for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 61.7% from the stock's current price.
View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts.

MannKind's stock was trading at $5.27 at the start of the year. Since then, MNKD stock has decreased by 23.7% and is now trading at $4.02.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our MNKD earnings forecast.

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Thursday, February, 23rd. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The biopharmaceutical company had revenue of $36.06 million for the quarter, compared to analysts' expectations of $35.51 million. The firm's quarterly revenue was up 188.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.11) EPS.

ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Global X Aging Population ETF (AGNG), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA SmallCap Momentum ETF (DWAS).

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.37%), Geode Capital Management LLC (1.87%), Emerald Advisers LLC (1.41%), Schonfeld Strategic Advisors LLC (1.09%), Renaissance Technologies LLC (0.74%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends.

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MNKD stock can currently be purchased for approximately $4.02.

MannKind (NASDAQ:MNKD) has a market capitalization of $1.06 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

The company employs 348 workers across the globe.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.